- Home
- ACLX
ACLX
Arcellx Inc.
as 04-18-2025 1:30pm EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.3B | IPO Year: | 2022 |
| Target Price: | $110.82 | AVG Volume (30 days): | 799.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.88 - $107.37 | Next Earning Date: | 05-08-2025 |
| Revenue: | $107,936,000 | Revenue Growth: | -2.16% |
| Revenue Growth (this year): | -14.22% | Revenue Growth (next year): | 96.17% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Kavita | ACLX | Director | Apr 8 '25 | Sell | $57.50 | 1,500 | $86,250.00 | 0 | |
| Patel Kavita | ACLX | Director | Mar 18 '25 | Sell | $71.64 | 1,500 | $107,460.00 | 0 | |
| Elghandour Rami | ACLX | SEE REMARKS | Feb 26 '25 | Sell | $61.92 | 38,300 | $2,375,517.24 | 149,186 | |
| Patel Kavita | ACLX | Director | Feb 25 '25 | Sell | $63.16 | 1,500 | $94,740.00 | 0 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Feb 24 '25 | Sell | $64.09 | 10,155 | $647,772.62 | 43,271 | |
| Patel Kavita | ACLX | Director | Feb 4 '25 | Sell | $64.57 | 1,500 | $96,855.00 | 0 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Insider Monkey
8 days ago
Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential
Business Wire
a month ago
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
Simply Wall St.
2 months ago
We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn
Zacks
2 months ago
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates
Business Wire
2 months ago
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
MT Newswires
2 months ago
Arcellx Insider Sold Shares Worth $2,375,517, According to a Recent SEC Filing
Business Wire
2 months ago
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
Insider Monkey
2 months ago
Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now?
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.